{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-057119","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.578186+00:00","generated_at":"2026-06-09T02:06:28.797577+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"EyePoint Q3 net loss narrows to $12.6M; revenue up 52% on YUTIQ royalty recognition","bullets":["Total net revenue $15.2M (up 52% YoY) driven by $14.4M in royalties from YUTIQ sale.","Net loss $12.6M ($0.33/share) vs $18.4M ($0.49/share); cash $136.0M at quarter end.","EYP-1901 Phase 2 DAVIO 2 topline wet AMD data expected Dec 2023; PAVIA data Q2 2024.","No drug-related SAEs in ongoing EYP-1901 trials; Phase 2 VERONA in DME to start Q1 2024.","Leadership: George Elston promoted to EVP; Stuart Duty appointed to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-057119","json":"https://secwatch.observer/filing/0000950170-23-057119.json","markdown":"https://secwatch.observer/filing/0000950170-23-057119.md","text":"https://secwatch.observer/filing/0000950170-23-057119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023057119/0000950170-23-057119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023057119/eypt-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:06:28.797577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f32b022a6a8d970a652a57f44805f315fa048cfd","claim":"EyePoint, Inc. reported the third quarter ended September 30, 2023 results: revenue $15.2 million, net income $(12.6) million, EPS ($0.33) per share.","evidence_excerpt":"For the third quarter ended September 30, 2023, total net revenue was $15.2 million compared to $10.0 million for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023057119/0000950170-23-057119-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$15.2 million"},{"label":"Net income","value":"$(12.6) million"},{"label":"EPS","value":"($0.33) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}